Patents by Inventor Elvira MASS

Elvira MASS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinase mutation-associated neurodegenerative disorders
    Patent number: 11957668
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-1R inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: April 16, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Frederic Geissmann, Elvira Mass, Rocio Vicario
  • KINASE MUTATION-ASSOCIATED NEURODEGENERATIVE DISORDERS
    Publication number: 20230277512
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-1R inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 7, 2023
    Inventors: Frederic GEISSMANN, Elvira MASS, Rocio VICARIO
  • Kinase mutation-associated neurodegenerative disorders
    Patent number: 11337965
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: May 24, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Frederic Geissmann, Elvira Mass, Rocio Vicario
  • KINASE MUTATION-ASSOCIATED NEURODEGENERATIVE DISORDERS
    Publication number: 20210315868
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Application
    Filed: August 24, 2018
    Publication date: October 14, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Frederic GEISSMANN, Elvira MASS, Rocio VICARIO